Welcome to our dedicated page for GMTX news (Ticker: GMTX), a resource for investors and traders seeking the latest updates and insights on GMTX stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect GMTX's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of GMTX's position in the market.
Gemini Therapeutics, a clinical stage precision medicine company focused on age-related macular degeneration (AMD), has announced that CEO Jason Meyenburg will participate in the Jefferies Virtual Healthcare Conference on June 2 at 3:30 PM ET. The event will be webcast live on the company's website, with a replay available for 30 days.
Gemini's lead therapy, GEM103, addresses complement hyperactivity to restore retinal health and is currently in clinical trials for AMD patients. The company also develops a range of therapies, advancing its pipeline of innovative treatments.
Gemini Therapeutics, Inc. (Nasdaq: GMTX) reported its Q1 2021 financial results and a business update. The company is advancing GEM103 in clinical trials for age-related macular degeneration (AMD) and recently completed enrollment in the Phase 2a trial of GEM103 for wet AMD. The FDA granted Fast Track Designation for GEM103 targeting dry AMD with genetic variants. Q1 expenses rose to $11.8 million in R&D and $4.7 million in G&A, leading to a net loss of $19.0 million. As of March 31, 2021, Gemini had $185.0 million in cash, positioning them well for future studies.
Gemini Therapeutics (Nasdaq: GMTX) announced the completion of enrollment in its Phase 2a trial of GEM103, aimed at patients with wet age-related macular degeneration (AMD). This potential add-on therapy targets those requiring continued anti-VEGF treatment and at risk for macular atrophy. Topline data on safety and biomarkers is expected in late 2021. The trial has overenrolled, indicating strong demand for improved treatments, highlighting GEM103's potential to address limitations of current therapies.
Gemini Therapeutics, Inc. (Nasdaq: GMTX) has appointed Georges Gemayel, Ph.D., as Chair of its Board of Directors. His extensive experience in the pharmaceutical sector, including roles at Supernus Pharmaceuticals and Genzyme Corporation, is expected to support the company’s clinical development efforts. CEO Jason Meyenburg highlighted that Dr. Gemayel's leadership will be crucial as Gemini advances its pipeline of precision medicines, particularly targeting age-related macular degeneration (AMD). Gemini's lead candidate, GEM103, is in clinical trials aimed at treating genetically defined AMD.
Gemini Therapeutics, Inc. (Nasdaq: GMTX) has presented preclinical data at the 2021 ARVO Virtual Annual Meeting, illustrating that their lead candidate GEM103 demonstrates anti-angiogenic activity in a mouse model for age-related macular degeneration (AMD). The use of human recombinant Complement Factor H (rhCFH) significantly diminished choroidal neovascularization (CNV) severity. GEM103 aims to treat genetically defined dry AMD patients and is currently undergoing clinical trials, with Fast Track Designation from the FDA for patients with CFH loss of function variants.
Gemini Therapeutics (Nasdaq: GMTX) announces the grant of inducement awards to CFO Brian Piekos and CMO Dr. Sam Barone as part of their employment agreements, approved by the Compensation Committee. Mr. Piekos receives an option to purchase 377,734 shares at $12.59 each, and Dr. Barone receives an option for 255,212 shares, both with a ten-year term and a four-year vesting schedule. The company is focused on developing treatments for age-related macular degeneration (AMD), with lead candidate GEM103 currently in clinical trials.
Gemini Therapeutics (Nasdaq: GMTX) has appointed Dr. Samuel Barone as Chief Medical Officer, effective immediately. Dr. Barone's extensive experience in retinal and macular diseases will support the company’s clinical pipeline as they advance their lead candidate, GEM103, currently in Phase 2a trials for dry age-related macular degeneration (AMD). He succeeds Dr. Marc E. Uknis, who will transition to an advisory role after contributing significantly to the company’s clinical development efforts.
Gemini Therapeutics, Inc. (Nasdaq: GMTX) reported its financial results for the year ending December 31, 2020, highlighting a net loss of $40.8 million, a slight decrease from $41.4 million in 2019. The company made significant strides in developing its lead program, GEM103, with successful Phase 1 results and ongoing Phase 2a trials targeting genetically-defined age-related macular degeneration (AMD). The company’s cash is expected to fund operations into 2023 following a business combination with FS Development Corp.
Gemini Therapeutics, a clinical stage precision medicine company focused on treatments for genetically defined age-related macular degeneration (AMD), announced that CEO Jason Meyeburg will present virtually at the SVB Leerink 10th Annual Global Healthcare Conference on February 25 at 1:00 PM ET. A live webcast will be accessible on the company’s website, with a replay available for 30 days afterward.
The company's lead candidate, GEM103, targets AMD by addressing complement hyperactivity and restoring retinal health, currently under Phase 2a trials.
Gemini Therapeutics, Inc. (Nasdaq: GMTX) has completed enrollment in its Phase 2a ReGAtta study, a trial assessing GEM103 for dry age-related macular degeneration (AMD) patients with CFH loss-of-function gene variants. This study aims to evaluate safety, tolerability, pharmacokinetics, and disease-relevant biomarkers. Approximately 40% of dry AMD patients carry CFH variants, and GEM103 is designed to specifically target these genetic markers. The company expects to release topline data in the first half of 2021, marking a significant step towards potential new treatment options for patients with geographic atrophy.
FAQ
What is the market cap of GMTX (GMTX)?
